{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:42:10Z","timestamp":1789965730678,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":586,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.5604\/01.3001.0010.5500","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T09:09:37Z","timestamp":1509181777000},"page":"S83-S86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"S1","title":["Bile Acids and Portal Hypertension"],"prefix":"10.1016","volume":"16","author":[{"given":"Juan","family":"Pablo Arab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0010.5500_bib0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hep.27249","article-title":"Prevention of portal hypertension: from variceal development to clinical decompensation","volume":"61","author":"Vorobioff","year":"2015","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0010.5500_bib0010","series-title":"Hepatol Int","article-title":"Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon","author":"Kang","year":"2017"},{"key":"10.5604\/01.3001.0010.5500_bib0015","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.27343","article-title":"Molecular pathophysiology of portal hypertension","volume":"61","author":"Fernandez","year":"2015","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0010.5500_bib0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","article-title":"The changing role of beta-blocker therapy in patients with cirrhosis","volume":"60","author":"Ge","year":"2014","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.5500_bib0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and de-compensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.5500_bib0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14728214.2016.1184647","article-title":"Emerging therapies for portal hypertension in cirrhosis","volume":"21","author":"Nair","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.5604\/01.3001.0010.5500_bib0035","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodeling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.5500_bib0040","doi-asserted-by":"crossref","first-page":"e0141082","DOI":"10.1371\/journal.pone.0141082","article-title":"Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT\/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1","volume":"10","author":"Renga","year":"2015","journal-title":"PLoS One"},{"key":"10.5604\/01.3001.0010.5500_bib0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0006-2952(94)00428-O","article-title":"Bile acids as endogenous vasodilators?","volume":"49","author":"Bomzon","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.5604\/01.3001.0010.5500_bib0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjp.0703554","article-title":"On the in vitro vasoactivity of bile acids","volume":"131","author":"Ljubuncic","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.5604\/01.3001.0010.5500_bib0055","first-page":"G366","article-title":"Differential effect of taurocholic acid on hepatic arterial resistance vessels and bile flow","volume":"244","author":"Lautt","year":"1983","journal-title":"Am J Physiol"},{"key":"10.5604\/01.3001.0010.5500_bib0060","doi-asserted-by":"crossref","first-page":"H21","DOI":"10.1152\/ajpheart.00577.2016","article-title":"Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators","volume":"312","author":"Fiorucci","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.5604\/01.3001.0010.5500_bib0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat Rev Gastroenterol Hepa-tol"},{"key":"10.5604\/01.3001.0010.5500_bib0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1752-8062.2011.00272.x","article-title":"Bile acids regulate cardiovascular function","volume":"4","author":"Khurana","year":"2011","journal-title":"Clin Transl Sci"},{"key":"10.5604\/01.3001.0010.5500_bib0075","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1210\/me.2009-0286","article-title":"FXR regulates liver repair after CCl4-induced toxic injury","volume":"24","author":"Meng","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.5604\/01.3001.0010.5500_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2012.05.004","article-title":"FXR signaling in the entero-hepatic system","volume":"368","author":"Matsubara","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.5604\/01.3001.0010.5500_bib0085","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.5604\/01.3001.0010.5500_bib0090","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.5604\/01.3001.0010.5500_bib0095","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J Immunol"},{"key":"10.5604\/01.3001.0010.5500_bib0100","series-title":"Hepa-tol Int","article-title":"Gut-liver axis cirrhosis and portal hypertension: the chicken and the egg","author":"Arab","year":"2017"},{"key":"10.5604\/01.3001.0010.5500_bib0105","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1161\/ATVBAHA.113.301565","article-title":"Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells","volume":"33","author":"Kida","year":"2013","journal-title":"Arterio-scler Thromb Vasc Biol"},{"key":"10.5604\/01.3001.0010.5500_bib0110","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1756283X16630712","article-title":"Novel bile acid therapeutics for the treatment of chronic liver diseases","volume":"9","author":"Hegade","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.5604\/01.3001.0010.5500_bib0115","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/14656566.2016.1218471","article-title":"Obeticholic acid for the treatment of primary biliary cholangitis","volume":"17","author":"Ali","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.5604\/01.3001.0010.5500_bib0120","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1021\/acs.jmedchem.7b00903","article-title":"Nonacidic Farnesoid X Receptor Modulators","volume":"60","author":"Flesch","year":"2017","journal-title":"J Med Chem"},{"key":"10.5604\/01.3001.0010.5500_bib0125","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0010.5500_bib0130","doi-asserted-by":"crossref","first-page":"e13955","DOI":"10.1371\/journal.pone.0013955","article-title":"Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.5604\/01.3001.0010.5500_bib0135","first-page":"529A","article-title":"Effect of the FXR agonist obeticholic acid on portal pressure in alcoholic cirrhosis: a phase 2 proof of concept study","volume":"56","author":"Mookerjee","year":"2012","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0010.5500_bib0140","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S0168-8278(17)30554-8","article-title":"TGR5 plays a protective role against portal hypertension in LCA induced liver damage in mice","volume":"66","author":"Klindt","year":"2017","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.5500_bib0145","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-8587(16)30155-3","article-title":"Clinical relevance of the bile acid receptor TGR5 in metabolism","volume":"5","author":"van Nierop","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119310464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119310464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:37:43Z","timestamp":1761647863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119310464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":29,"alternative-id":["S1665268119310464"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0010.5500","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile Acids and Portal Hypertension","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0010.5500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}